25 XP   0   0   10

Regulus Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Regulus Therapeutics Inc together

PenkeI guess you are interested in Regulus Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Regulus Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Regulus Therapeutics Inc

I send you an email if I find something interesting about Regulus Therapeutics Inc.

Quick analysis of Regulus Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Regulus Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.43
Expected worth in 1 year
$0.26
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.17
Return On Investment
-6.1%

For what price can you sell your share?

Current Price per Share
$2.88
Expected price per share
$1.76 - $3.4
How sure are you?
50%

1. Valuation of Regulus Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$2.88

Intrinsic Value Per Share

$-5.85 - $-3.53

Total Value Per Share

$-5.42 - $-3.10

2. Growth of Regulus Therapeutics Inc (5 min.)




Is Regulus Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$28.2m$46.5m-$16m-52.5%

How much money is Regulus Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m-$7.1m$1.2k0.0%
Net Profit Margin0.0%-17,796,906.2%--

How much money comes from the company's main activities?

3. Financial Health of Regulus Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#562 / 1031

Most Revenue
#837 / 1031

Most Profit
#526 / 1031

Most Efficient
#290 / 1031

What can you expect buying and holding a share of Regulus Therapeutics Inc? (5 min.)

Welcome investor! Regulus Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Regulus Therapeutics Inc.

What can you expect buying and holding a share of Regulus Therapeutics Inc?

First you should know what it really means to hold a share of Regulus Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Regulus Therapeutics Inc is $2.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Regulus Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Regulus Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.43. Based on the TTM, the Book Value Change Per Share is $-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Regulus Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-4.1%-0.11-3.8%-0.11-3.8%-0.09-3.2%-0.16-5.7%
Usd Book Value Change Per Share-0.09-3.0%-0.04-1.5%0.041.4%0.020.7%-0.03-0.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-3.0%-0.04-1.5%0.041.4%0.020.7%-0.03-0.9%
Usd Price Per Share1.37-1.26-1.10-1.02-3.32-
Price to Earnings Ratio-2.87--2.89--2.45--3.52--6.33-
Price-to-Total Gains Ratio-15.63--6.24--15.90--18.07--47.09-
Price to Book Ratio3.17-2.70-1.69--14.58--5.07-
Price-to-Total Gains Ratio-15.63--6.24--15.90--18.07--47.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.88
Number of shares347
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.02
Usd Total Gains Per Share-0.040.02
Gains per Quarter (347 shares)-15.127.07
Gains per Year (347 shares)-60.4928.29
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-60-7002818
20-121-13005746
30-181-19008574
40-242-2500113102
50-302-3100141130
60-363-3700170158
70-423-4300198186
80-484-4900226214
90-544-5500255242
100-605-6100283270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.049.01.00.0%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%10.030.00.025.0%14.034.02.028.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.050.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%10.030.00.025.0%14.034.02.028.0%

Fundamentals of Regulus Therapeutics Inc

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-03-22 02:04:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Regulus Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Regulus Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Regulus Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-17,796,906.2%+17,796,906.2%
TTM-5Y-3,600,332.1%+3,600,332.1%
5Y-3,600,332.1%10Y-1,819,104.2%-1,781,228.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY-17,796,906.2%-263.0%-17,796,643.2%
5Y-3,600,332.1%-452.4%-3,599,879.7%
10Y-1,819,104.2%-589.0%-1,818,515.2%
1.1.2. Return on Assets

Shows how efficient Regulus Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • -20.7% Return on Assets means that Regulus Therapeutics Inc generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Regulus Therapeutics Inc:

  • The MRQ is -20.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.7%TTM-17.6%-3.1%
TTM-17.6%YOY-12.4%-5.3%
TTM-17.6%5Y-16.0%-1.6%
5Y-16.0%10Y-16.3%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.7%-12.5%-8.2%
TTM-17.6%-12.2%-5.4%
YOY-12.4%-11.2%-1.2%
5Y-16.0%-13.3%-2.7%
10Y-16.3%-14.6%-1.7%
1.1.3. Return on Equity

Shows how efficient Regulus Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • -27.7% Return on Equity means Regulus Therapeutics Inc generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Regulus Therapeutics Inc:

  • The MRQ is -27.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.7%TTM-23.9%-3.8%
TTM-23.9%YOY-15.7%-8.1%
TTM-23.9%5Y-25.1%+1.3%
5Y-25.1%10Y-45.0%+19.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.7%-16.0%-11.7%
TTM-23.9%-15.8%-8.1%
YOY-15.7%-13.9%-1.8%
5Y-25.1%-18.2%-6.9%
10Y-45.0%-19.1%-25.9%

1.2. Operating Efficiency of Regulus Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Regulus Therapeutics Inc is operating .

  • Measures how much profit Regulus Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Regulus Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-17,467,564.9%+17,467,564.9%
TTM-5Y-3,532,825.0%+3,532,825.0%
5Y-3,532,825.0%10Y-1,784,759.9%-1,748,065.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY-17,467,564.9%-280.2%-17,467,284.7%
5Y-3,532,825.0%-459.9%-3,532,365.1%
10Y-1,784,759.9%-596.9%-1,784,163.0%
1.2.2. Operating Ratio

Measures how efficient Regulus Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Regulus Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY173,652.695-173,652.695
TTM-5Y35,172.327-35,172.327
5Y35,172.32710Y17,933.152+17,239.175
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY173,652.6953.609+173,649.086
5Y35,172.3275.554+35,166.773
10Y17,933.1527.396+17,925.756

1.3. Liquidity of Regulus Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Regulus Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.25 means the company has $4.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Regulus Therapeutics Inc:

  • The MRQ is 4.253. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.245. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.253TTM4.245+0.009
TTM4.245YOY9.579-5.334
TTM4.2455Y4.007+0.238
5Y4.00710Y6.469-2.461
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2533.987+0.266
TTM4.2454.440-0.195
YOY9.5795.569+4.010
5Y4.0076.158-2.151
10Y6.4696.492-0.023
1.3.2. Quick Ratio

Measures if Regulus Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.33 means the company can pay off $4.33 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Regulus Therapeutics Inc:

  • The MRQ is 4.332. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.300. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.332TTM4.300+0.032
TTM4.300YOY10.077-5.777
TTM4.3005Y3.943+0.357
5Y3.94310Y9.598-5.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3323.653+0.679
TTM4.3004.158+0.142
YOY10.0775.515+4.562
5Y3.9436.012-2.069
10Y9.5986.206+3.392

1.4. Solvency of Regulus Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Regulus Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Regulus Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Regulus Therapeutics Inc assets are financed with 25.1% credit (debt) and the remaining percentage (100% - 25.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Regulus Therapeutics Inc:

  • The MRQ is 0.251. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.260. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.251TTM0.260-0.009
TTM0.260YOY0.212+0.048
TTM0.2605Y0.498-0.238
5Y0.49810Y0.440+0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2510.336-0.085
TTM0.2600.330-0.070
YOY0.2120.267-0.055
5Y0.4980.367+0.131
10Y0.4400.378+0.062
1.4.2. Debt to Equity Ratio

Measures if Regulus Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.6% means that company has $0.34 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Regulus Therapeutics Inc:

  • The MRQ is 0.336. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.354. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.336TTM0.354-0.018
TTM0.354YOY0.270+0.084
TTM0.3545Y0.805-0.451
5Y0.80510Y1.304-0.499
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3360.376-0.040
TTM0.3540.398-0.044
YOY0.2700.334-0.064
5Y0.8050.431+0.374
10Y1.3040.476+0.828

2. Market Valuation of Regulus Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Regulus Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Regulus Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.87 means the investor is paying $-2.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Regulus Therapeutics Inc:

  • The EOD is -6.024. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.866. Based on the earnings, the company is expensive. -2
  • The TTM is -2.893. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.024MRQ-2.866-3.159
MRQ-2.866TTM-2.893+0.028
TTM-2.893YOY-2.450-0.443
TTM-2.8935Y-3.519+0.625
5Y-3.51910Y-6.330+2.811
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.024-2.697-3.327
MRQ-2.866-2.422-0.444
TTM-2.893-2.709-0.184
YOY-2.450-4.116+1.666
5Y-3.519-6.257+2.738
10Y-6.330-6.478+0.148
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Regulus Therapeutics Inc:

  • The EOD is -6.913. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.289. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.099. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.913MRQ-3.289-3.625
MRQ-3.289TTM-3.099-0.190
TTM-3.099YOY-2.718-0.381
TTM-3.0995Y-2.377-0.722
5Y-2.37710Y-5.264+2.887
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.913-3.344-3.569
MRQ-3.289-2.939-0.350
TTM-3.099-3.486+0.387
YOY-2.718-5.592+2.874
5Y-2.377-8.464+6.087
10Y-5.264-8.872+3.608
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Regulus Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.17 means the investor is paying $3.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Regulus Therapeutics Inc:

  • The EOD is 6.672. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.174. Based on the equity, the company is fair priced.
  • The TTM is 2.696. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD6.672MRQ3.174+3.498
MRQ3.174TTM2.696+0.478
TTM2.696YOY1.694+1.002
TTM2.6965Y-14.578+17.274
5Y-14.57810Y-5.066-9.512
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.6722.198+4.474
MRQ3.1742.042+1.132
TTM2.6962.121+0.575
YOY1.6942.907-1.213
5Y-14.5783.682-18.260
10Y-5.0664.114-9.180
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Regulus Therapeutics Inc.

3.1. Institutions holding Regulus Therapeutics Inc

Institutions are holding 25.302% of the shares of Regulus Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Inc19.16450.0123387557800
2023-12-31FMR Inc14.45210.0003292260000
2023-12-31NEA Management Company, LLC9.62080.166194557900
2023-12-31Dafna Capital Management LLC5.49410.3408111104900
2023-12-31Vanguard Group Inc1.4164028643113810.4845
2023-12-31Victory Capital Management Inc.1.34370.00042717363852916.5214
2023-09-30Sarissa Capital Management LP0.91570.034218518300
2023-12-31Exome Asset Management LLC0.88220.22581784041784040
2023-12-31Geode Capital Management, LLC0.6059012252100
2023-12-31Renaissance Technologies Corp0.270.00015460045008.982
2023-12-31State Street Corporation0.206304171900
2023-12-31Springbok Capital Management, LLC0.19910.00344026000
2023-12-31Northern Trust Corp0.088901797800
2023-12-31Commonwealth Equity Services Inc0.086501750000
2023-09-30Citadel Advisors Llc0.0579011715-16090-57.8673
2023-12-31Grimes & Company, Inc.0.05150.000410420-127-1.2041
2023-12-31Citigroup Inc0.01050212321230
2023-12-31Community Bank NA0.00340.000169000
2023-12-31BlackRock Inc0.00280573-45-7.2816
2023-12-31Acadian Asset Management LLC0.0023046600
Total 54.87460.783811097125+208675+1.9%

3.2. Funds holding Regulus Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Kaufmann Small Cap Grow16.73320.2293338390000
2023-12-31Federated Hermes Kaufmann Small Cap A16.5260.1017334200000
2023-12-31Federated Hermes Kaufmann Growth15.56670.2048314800000
2023-12-31Federated Hermes Kaufmann R15.33430.0814310100000
2024-01-31Fidelity Select Biotechnology14.45210.0805292260000
2023-12-31Victory Science & Technology6.69560.1016135403725677123.401
2024-02-29Vanguard Total Stock Mkt Idx Inv2.3342047202814000042.1651
2023-12-31Victory RS Science and Technology A1.57380.135231825587702.8337
2023-12-31RS Science And Technology Composite0.91790.135218561887704.9591
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.60190.000212172200
2024-01-31Fidelity Extended Market Index0.42310.00038557000
2023-12-31Federated Hermes Kaufmann II P0.41190.08638330700
2024-01-31Fidelity Series Total Market Index0.075101517800
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05160.00021043700
2023-12-31Northern Trust Extended Eq Market Idx0.05160.00021043700
2024-01-31Fidelity Nasdaq Composite Index0.04550.0001920500
2024-01-31Schwab Total Stock Market Index0.04510.0001911300
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03030.0001613700
2024-01-31Spartan Total Market Index Pool E0.02530512600
2024-01-31Fidelity Total Market Index0.02510507600
Total 91.92031.157218588746+414311+2.2%

3.3. Insider Transactions

Insiders are holding 1.415% of the shares of Regulus Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-18Crispina CalsadaSELL54681.19
2024-01-18Joseph P HaganSELL145801.19

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Regulus Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.088-0.044-50%0.041-315%0.020-530%-0.025-71%
Book Value Per Share--0.4320.466-7%0.711-39%0.360+20%0.755-43%
Current Ratio--4.2534.245+0%9.579-56%4.007+6%6.469-34%
Debt To Asset Ratio--0.2510.260-3%0.212+19%0.498-50%0.440-43%
Debt To Equity Ratio--0.3360.354-5%0.270+24%0.805-58%1.304-74%
Dividend Per Share----0%-0%-0%-0%
Eps---0.120-0.109-8%-0.109-8%-0.092-23%-0.164+37%
Free Cash Flow Per Share---0.104-0.105+1%-0.105+1%-0.082-21%-0.140+34%
Free Cash Flow To Equity Per Share---0.100-0.057-43%0.036-376%0.008-1413%-0.017-83%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.527--------
Intrinsic Value_10Y_min---5.852--------
Intrinsic Value_1Y_max---0.348--------
Intrinsic Value_1Y_min---0.567--------
Intrinsic Value_3Y_max---1.050--------
Intrinsic Value_3Y_min---1.730--------
Intrinsic Value_5Y_max---1.756--------
Intrinsic Value_5Y_min---2.914--------
Market Cap188536320.000+52%89685680.00082771045.000+8%71732178.000+25%66515679.160+35%217129685.920-59%
Net Profit Margin----0%-177969.0620%-36003.3210%-18191.0420%
Operating Margin----0%-174675.6490%-35328.2500%-17847.5990%
Operating Ratio----0%173652.695-100%35172.327-100%17933.152-100%
Pb Ratio6.672+52%3.1742.696+18%1.694+87%-14.578+559%-5.066+260%
Pe Ratio-6.024-110%-2.866-2.893+1%-2.450-14%-3.519+23%-6.330+121%
Price Per Share2.880+52%1.3701.264+8%1.096+25%1.016+35%3.317-59%
Price To Free Cash Flow Ratio-6.913-110%-3.289-3.099-6%-2.718-17%-2.377-28%-5.264+60%
Price To Total Gains Ratio-32.857-110%-15.630-6.244-60%-15.899+2%-18.069+16%-47.092+201%
Quick Ratio--4.3324.300+1%10.077-57%3.943+10%9.598-55%
Return On Assets---0.207-0.176-15%-0.124-40%-0.160-23%-0.163-22%
Return On Equity---0.277-0.239-14%-0.157-43%-0.251-9%-0.450+62%
Total Gains Per Share---0.088-0.044-50%0.041-315%0.020-530%-0.025-71%
Usd Book Value--28259000.00030535500.000-7%46559000.000-39%23564350.000+20%49411075.000-43%
Usd Book Value Change Per Share---0.088-0.044-50%0.041-315%0.020-530%-0.025-71%
Usd Book Value Per Share--0.4320.466-7%0.711-39%0.360+20%0.755-43%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.120-0.109-8%-0.109-8%-0.092-23%-0.164+37%
Usd Free Cash Flow---6818000.000-6875250.000+1%-6860750.000+1%-5392300.000-21%-9138100.000+34%
Usd Free Cash Flow Per Share---0.104-0.105+1%-0.105+1%-0.082-21%-0.140+34%
Usd Free Cash Flow To Equity Per Share---0.100-0.057-43%0.036-376%0.008-1413%-0.017-83%
Usd Market Cap188536320.000+52%89685680.00082771045.000+8%71732178.000+25%66515679.160+35%217129685.920-59%
Usd Price Per Share2.880+52%1.3701.264+8%1.096+25%1.016+35%3.317-59%
Usd Profit---7824000.000-7181750.000-8%-7183000.000-8%-6050950.000-23%-10731500.000+37%
Usd Revenue----0%2.505-100%1093050.101-100%1426575.051-100%
Usd Total Gains Per Share---0.088-0.044-50%0.041-315%0.020-530%-0.025-71%
 EOD+5 -3MRQTTM+11 -18YOY+10 -215Y+13 -1810Y+12 -19

4.2. Fundamental Score

Let's check the fundamental score of Regulus Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.024
Price to Book Ratio (EOD)Between0-16.672
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.332
Current Ratio (MRQ)Greater than14.253
Debt to Asset Ratio (MRQ)Less than10.251
Debt to Equity Ratio (MRQ)Less than10.336
Return on Equity (MRQ)Greater than0.15-0.277
Return on Assets (MRQ)Greater than0.05-0.207
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Regulus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.919
Ma 20Greater thanMa 502.182
Ma 50Greater thanMa 1001.707
Ma 100Greater thanMa 2001.520
OpenGreater thanClose2.810
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets37,747
Total Liabilities9,488
Total Stockholder Equity28,259
 As reported
Total Liabilities 9,488
Total Stockholder Equity+ 28,259
Total Assets = 37,747

Assets

Total Assets37,747
Total Current Assets35,082
Long-term Assets2,665
Total Current Assets
Cash And Cash Equivalents 25,833
Short-term Investments 4,949
Other Current Assets 1,228
Total Current Assets  (as reported)35,082
Total Current Assets  (calculated)32,010
+/- 3,072
Long-term Assets
Property Plant Equipment 2,629
Intangible Assets 36
Long-term Assets  (as reported)2,665
Long-term Assets  (calculated)2,665
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,248
Long-term Liabilities1,240
Total Stockholder Equity28,259
Total Current Liabilities
Short-term Debt 2,128
Short Long Term Debt 2,128
Accounts payable 599
Other Current Liabilities 1,970
Total Current Liabilities  (as reported)8,248
Total Current Liabilities  (calculated)6,825
+/- 1,423
Long-term Liabilities
Capital Lease Obligations 1,240
Long-term Liabilities  (as reported)1,240
Long-term Liabilities  (calculated)1,240
+/-0
Total Stockholder Equity
Common Stock20
Retained Earnings -505,152
Other Stockholders Equity 533,387
Total Stockholder Equity (as reported)28,259
Total Stockholder Equity (calculated)28,255
+/- 4
Other
Capital Stock25
Cash and Short Term Investments 30,782
Common Stock Shares Outstanding 19,629
Current Deferred Revenue3,551
Liabilities and Stockholders Equity 37,747
Net Debt -22,465
Net Invested Capital 30,382
Net Working Capital 26,834
Property Plant and Equipment Gross 2,629
Short Long Term Debt Total 3,368



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-12-31
> Total Assets 
59,703
0
42,881
0
33,187
40,723
103,518
97,027
92,517
130,590
123,065
124,107
113,921
104,015
171,480
164,848
150,265
143,447
141,083
128,138
129,928
116,266
100,661
80,174
61,860
90,847
77,809
62,079
49,170
34,768
27,927
19,877
25,691
21,410
42,081
35,006
29,782
27,343
37,604
39,841
49,516
43,042
68,454
60,985
54,298
52,127
46,716
37,015
43,647
37,747
37,74743,64737,01546,71652,12754,29860,98568,45443,04249,51639,84137,60427,34329,78235,00642,08121,41025,69119,87727,92734,76849,17062,07977,80990,84761,86080,174100,661116,266129,928128,138141,083143,447150,265164,848171,480104,015113,921124,107123,065130,59092,51797,027103,51840,72333,187042,881059,703
   > Total Current Assets 
0
0
38,666
0
27,601
34,359
98,929
91,769
86,873
125,286
117,182
118,229
107,884
98,023
164,951
158,517
144,089
136,810
134,258
115,759
116,234
102,830
87,474
67,649
49,944
79,566
66,736
51,428
39,231
25,441
19,295
17,739
24,284
19,529
40,407
33,607
28,589
26,307
36,730
36,537
46,313
39,986
65,235
57,933
51,396
49,373
44,079
34,562
41,363
35,082
35,08241,36334,56244,07949,37351,39657,93365,23539,98646,31336,53736,73026,30728,58933,60740,40719,52924,28417,73919,29525,44139,23151,42866,73679,56649,94467,64987,474102,830116,234115,759134,258136,810144,089158,517164,95198,023107,884118,229117,182125,28686,87391,76998,92934,35927,601038,66600
       Cash And Cash Equivalents 
21,268
0
9,175
0
4,928
17,426
40,552
90,715
82,715
123,903
114,005
8,476
10,024
94,065
37,327
19,600
139,368
18,324
115,319
19,249
108,004
91,663
76,111
14,889
12,538
20,222
13,519
10,057
13,485
14,084
13,935
10,320
19,571
14,646
34,121
28,052
23,419
17,843
31,087
31,597
41,440
35,848
60,383
53,902
35,119
20,014
24,228
30,308
37,263
25,833
25,83337,26330,30824,22820,01435,11953,90260,38335,84841,44031,59731,08717,84323,41928,05234,12114,64619,57110,32013,93514,08413,48510,05713,51920,22212,53814,88976,11191,663108,00419,249115,31918,324139,36819,60037,32794,06510,0248,476114,005123,90382,71590,71540,55217,4264,92809,175021,268
       Short-term Investments 
33,521
0
28,969
0
22,086
13,467
57,548
72,893
63,545
90,413
96,198
106,121
93,477
84,107
122,416
129,191
118,284
112,002
98,103
85,849
80,502
76,877
61,170
42,575
27,549
51,148
46,555
35,077
19,371
6,433
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,415
25,310
14,932
0
0
4,949
4,9490014,93225,31012,415000000000000006,43319,37135,07746,55551,14827,54942,57561,17076,87780,50285,84998,103112,002118,284129,191122,41684,10793,477106,12196,19890,41363,54572,89357,54813,46722,086028,969033,521
       Net Receivables 
0
0
0
0
0
3,000
0
0
2,538
95
79
140
0
0
274
4,859
616
325
10,021
61
143
286
1,657
439
690
532
373
188
184
13
26
2,792
331
699
1,141
676
674
4,000
503
72
194
0
0
8
0
3,069
3,069
4
3
0
0343,0693,0690800194725034,0006746761,1416993312,79226131841883735326904391,6572861436110,0213256164,8592740014079952,538003,00000000
       Inventory 
0
0
0
0
0
0
0
0
-2,538
-95
-79
0
0
0
0
0
-616
0
-10,021
10,190
-143
-286
5,552
6,212
6,149
5,912
4,783
4,783
0
0
4,194
3,826
3,826
3,826
3,924
3,924
3,923
3,388
3,314
3,376
3,331
3,010
3,010
3,072
3,010
3
3
3,072
3,072
0
03,0723,072333,0103,0723,0103,0103,3313,3763,3143,3883,9233,9243,9243,8263,8263,8264,194004,7834,7835,9126,1496,2125,552-286-14310,190-10,0210-61600000-79-95-2,53800000000
   > Long-term Assets 
0
0
4,215
0
5,586
6,364
4,589
5,258
5,644
5,304
5,883
5,878
6,037
5,992
6,529
6,331
6,176
6,637
6,825
12,379
13,694
13,436
13,187
12,525
11,916
11,281
11,073
10,651
9,939
9,327
8,632
2,138
1,407
1,881
1,674
1,399
1,193
1,036
874
3,304
3,203
3,056
3,219
3,052
2,902
2,754
2,637
2,453
2,284
2,665
2,6652,2842,4532,6372,7542,9023,0523,2193,0563,2033,3048741,0361,1931,3991,6741,8811,4072,1388,6329,3279,93910,65111,07311,28111,91612,52513,18713,43613,69412,3796,8256,6376,1766,3316,5295,9926,0375,8785,8835,3045,6445,2584,5896,3645,58604,21500
       Property Plant Equipment 
3,458
0
3,110
0
3,425
3,144
3,310
3,892
4,011
3,981
3,768
3,805
3,948
3,840
3,568
3,444
3,310
3,488
5,400
10,956
12,322
12,042
11,830
11,270
10,753
10,172
9,708
9,305
8,906
8,324
7,806
1,598
974
1,042
921
801
684
574
472
3,188
3,098
2,967
2,845
2,830
2,832
2,687
2,575
2,395
2,245
2,629
2,6292,2452,3952,5752,6872,8322,8302,8452,9673,0983,1884725746848019211,0429741,5987,8068,3248,9069,3059,70810,17210,75311,27011,83012,04212,32210,9565,4003,4883,3103,4443,5683,8403,9483,8053,7683,9814,0113,8923,3103,1443,42503,11003,458
       Intangible Assets 
945
0
980
0
1,107
1,124
1,154
1,176
1,229
1,145
1,128
1,095
1,112
1,114
1,150
1,087
1,072
1,072
1,081
1,069
1,062
1,051
1,015
920
823
802
775
726
705
676
500
407
406
303
266
159
122
129
125
116
105
89
83
74
70
67
62
58
39
36
3639586267707483891051161251291221592663034064075006767057267758028239201,0151,0511,0621,0691,0811,0721,0721,0871,1501,1141,1121,0951,1281,1451,2291,1761,1541,1241,10709800945
       Long-term Assets Other 
0
0
125
0
1,054
2,096
125
190
404
178
987
978
977
1,038
1,811
1,800
1,794
2,077
344
354
310
343
342
335
340
307
590
620
328
327
326
133
27
536
487
439
387
333
277
116
105
89
291
148
70
0
0
0
0
0
000007014829189105116277333387439487536271333263273286205903073403353423433103543442,0771,7941,8001,8111,0389779789871784041901252,0961,054012500
> Total Liabilities 
51,707
0
84,375
0
30,703
91,871
41,425
41,160
43,196
36,144
29,608
31,820
31,838
29,935
39,466
18,023
17,638
17,585
17,005
20,909
41,482
43,581
44,586
41,446
41,865
42,265
42,593
39,203
38,737
33,190
33,781
25,946
20,948
21,553
22,066
20,104
21,198
19,589
11,578
12,730
12,688
14,030
13,496
11,744
11,931
12,457
13,425
10,420
9,650
9,488
9,4889,65010,42013,42512,45711,93111,74413,49614,03012,68812,73011,57819,58921,19820,10422,06621,55320,94825,94633,78133,19038,73739,20342,59342,26541,86541,44644,58643,58141,48220,90917,00517,58517,63818,02339,46629,93531,83831,82029,60836,14443,19641,16041,42591,87130,703084,375051,707
   > Total Current Liabilities 
14,729
0
12,850
0
16,795
13,407
12,768
12,693
4,129
13,527
5,482
9,568
11,267
7,719
8,698
14,351
11,515
14,809
11,438
11,012
10,839
13,080
13,735
10,577
11,123
11,758
32,600
30,933
30,799
25,654
26,646
24,840
20,487
21,004
21,598
19,786
20,981
19,479
11,578
9,864
9,968
11,460
5,227
4,701
5,829
10,521
11,657
8,822
8,229
8,248
8,2488,2298,82211,65710,5215,8294,7015,22711,4609,9689,86411,57819,47920,98119,78621,59821,00420,48724,84026,64625,65430,79930,93332,60011,75811,12310,57713,73513,08010,83911,01211,43814,80911,51514,3518,6987,71911,2679,5685,48213,5274,12912,69312,76813,40716,795012,850014,729
       Short-term Debt 
0
0
377
0
5,204
115
0
-398
-14,876
-1,140
-4,888
0
0
-4,174
23,397
0
-3,032
0
-1,194
0
-258
-72
-72
19,816
19,830
19,845
19,859
19,874
19,888
19,069
16,575
15,225
14,621
14,626
14,631
14,636
14,642
13,647
4,652
4,657
4,662
4,668
4,673
826
1,652
4,478
4,511
3,716
2,922
2,128
2,1282,9223,7164,5114,4781,6528264,6734,6684,6624,6574,65213,64714,64214,63614,63114,62614,62115,22516,57519,06919,88819,87419,85919,84519,83019,816-72-72-2580-1,1940-3,032023,397-4,17400-4,888-1,140-14,876-39801155,204037700
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,397
0
0
0
0
0
0
0
19,802
19,816
19,830
19,845
19,859
19,874
19,888
19,069
16,575
15,225
14,621
14,626
14,631
14,636
14,642
13,647
4,652
4,657
4,662
4,668
0
826
1,652
4,478
4,511
3,716
2,922
2,128
2,1282,9223,7164,5114,4781,65282604,6684,6624,6574,65213,64714,64214,63614,63114,62614,62115,22516,57519,06919,88819,87419,85919,84519,83019,81619,802000000023,39700000000000000
       Accounts payable 
1,294
0
501
0
762
649
311
398
1,028
1,140
1,172
2,691
3,018
2,642
2,188
2,677
2,407
3,392
2,717
3,622
3,504
5,724
5,840
4,509
4,901
5,229
5,743
4,396
5,468
1,235
1,714
2,650
1,602
1,521
1,321
1,030
1,024
1,102
535
810
1,393
586
285
625
595
796
175
581
362
599
5993625811757965956252855861,3938105351,1021,0241,0301,3211,5211,6022,6501,7141,2355,4684,3965,7435,2294,9014,5095,8405,7243,5043,6222,7173,3922,4072,6772,1882,6423,0182,6911,1721,1401,028398311649762050101,294
       Other Current Liabilities 
13,022
0
1,237
0
2,594
2,050
2,006
3,492
3,101
4,073
4,310
4,138
5,619
5,077
-19,984
6,367
9,108
9,408
8,721
6,667
7,335
7,356
7,895
5,996
6,150
6,457
6,926
2,176
2,130
2,202
5,785
6,905
4,222
4,833
5,640
2,728
3,295
2,381
2,970
2,249
1,516
1,657
4,942
3,250
3,582
5,247
6,971
4,525
2,036
1,970
1,9702,0364,5256,9715,2473,5823,2504,9421,6571,5162,2492,9702,3813,2952,7285,6404,8334,2226,9055,7852,2022,1302,1766,9266,4576,1505,9967,8957,3567,3356,6678,7219,4089,1086,367-19,9845,0775,6194,1384,3104,0733,1013,4922,0062,0502,59401,237013,022
   > Long-term Liabilities 
0
0
71,525
0
13,908
78,464
28,657
28,467
39,067
22,617
24,126
22,252
20,571
22,216
30,768
3,672
6,123
2,776
5,567
9,897
30,643
30,501
30,851
30,869
30,742
30,507
9,993
8,270
7,938
7,536
7,135
1,106
461
549
468
318
217
110
0
2,866
2,720
2,570
8,269
7,043
6,102
1,936
1,768
1,598
1,421
1,240
1,2401,4211,5981,7681,9366,1027,0438,2692,5702,7202,86601102173184685494611,1067,1357,5367,9388,2709,99330,50730,74230,86930,85130,50130,6439,8975,5672,7766,1233,67230,76822,21620,57122,25224,12622,61739,06728,46728,65778,46413,908071,52500
       Long term Debt Total 
0
0
0
0
0
10,000
15,534
11,895
14,592
13,921
11,279
13,403
12,450
10,665
0
0
0
0
0
0
19,786
19,787
19,802
19,816
19,830
19,845
0
0
0
0
0
245
200
114
56
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000561142002450000019,84519,83019,81619,80219,78719,78600000010,66512,45013,40311,27913,92114,59211,89515,53410,00000000
       Capital Lease Obligations Min Short Term Debt
0
0
-377
0
-5,204
-115
0
398
14,876
1,140
4,888
0
0
4,174
-23,397
0
3,032
0
1,194
0
258
72
72
-19,816
-19,830
-19,845
-19,859
-19,874
-19,888
-19,069
-16,575
-15,225
-14,621
-14,626
-14,631
-14,636
-14,642
-13,647
-4,652
-1,791
-1,942
-2,098
-2,256
1,436
450
-2,542
-2,743
-2,118
-1,501
-888
-888-1,501-2,118-2,743-2,5424501,436-2,256-2,098-1,942-1,791-4,652-13,647-14,642-14,636-14,631-14,626-14,621-15,225-16,575-19,069-19,888-19,874-19,859-19,845-19,830-19,816727225801,19403,0320-23,3974,174004,8881,14014,8763980-115-5,2040-37700
       Warrants
0
0
0
0
0
42,691
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000042,69100000
       Long-term Liabilities Other 
0
0
0
0
0
8,670
767
804
1,765
1,558
1,459
1,361
1,260
1,142
1,022
903
804
693
2,308
7,850
8,570
8,631
144
214
283
351
0
438
7,938
7,536
7,135
1,106
461
549
468
318
217
110
0
2,866
2,720
0
1,179
1,193
1,206
0
0
0
0
0
000001,2061,1931,17902,7202,86601102173184685494611,1067,1357,5367,93843803512832141448,6318,5707,8502,3086938049031,0221,1421,2601,3611,4591,5581,7658047678,67000000
       Deferred Long Term Liability 
0
0
0
0
0
17,103
17,756
15,768
7,834
7,138
6,500
7,488
6,861
6,235
3,252
2,769
2,287
2,083
2,065
2,047
2,029
2,011
10,833
10,839
10,629
10,311
9,993
7,832
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000007,8329,99310,31110,62910,83910,8332,0112,0292,0472,0652,0832,2872,7693,2526,2356,8617,4886,5007,1387,83415,76817,75617,10300000
> Total Stockholder Equity
7,996
0
-41,494
0
2,484
-51,148
62,093
55,867
49,321
94,446
93,457
92,287
82,083
74,080
132,014
146,825
132,627
125,862
124,078
107,229
88,446
72,685
56,075
38,728
19,995
48,582
35,216
22,876
10,433
1,578
-5,854
-6,069
4,743
-143
20,015
14,902
8,584
7,754
26,026
27,111
36,828
29,012
54,958
49,241
42,367
39,670
33,291
26,595
33,997
28,259
28,25933,99726,59533,29139,67042,36749,24154,95829,01236,82827,11126,0267,7548,58414,90220,015-1434,743-6,069-5,8541,57810,43322,87635,21648,58219,99538,72856,07572,68588,446107,229124,078125,862132,627146,825132,01474,08082,08392,28793,45794,44649,32155,86762,093-51,1482,4840-41,49407,996
   Common Stock
0
0
0
0
15
23
36
36
36
42
42
43
43
43
49
51
52
52
53
53
53
53
53
53
53
104
104
104
104
9
9
11
21
21
21
22
36
39
67
75
87
87
146
146
15
17
17
17
19
20
2019171717151461468787756739362221212111991041041041045353535353535352525149434343424236363623150000
   Retained Earnings Total Equity0-497,3280000000-439,092-433,058-427,045-425,723-424,199-417,252-411,315-406,422-400,999-395,983-392,723-384,161-373,887-360,040-345,858-331,410-315,582-293,974-273,351-253,331-233,811-212,722-191,515-184,289-171,289-150,254-135,767-113,599-103,801-91,828-79,087-77,160-74,996-67,648-60,419-53,54300000
   Accumulated Other Comprehensive Income -1-10-12-31-3600000000-4,410-4,41000-9,894-9,894-63-80-127-134-104-88-97-123-113-83-92-133-134-155-163-197-66-42-59-16-44-82-37-52-23-330-6700
   Capital Surplus 
0
0
0
0
0
2,418
122,528
123,516
124,363
171,608
172,518
184,131
185,883
187,702
267,929
297,191
304,019
310,233
315,673
319,990
322,287
326,076
329,496
332,746
335,612
379,992
381,104
382,939
384,296
385,793
386,860
389,903
405,721
406,258
431,305
432,129
432,745
433,436
453,002
460,092
475,831
0
0
0
0
0
0
0
531,301
0
0531,3010000000475,831460,092453,002433,436432,745432,129431,305406,258405,721389,903386,860385,793384,296382,939381,104379,992335,612332,746329,496326,076322,287319,990315,673310,233304,019297,191267,929187,702185,883184,131172,518171,608124,363123,516122,5282,41800000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
1,584
0
52,272
-40,296
124,918
123,479
124,281
171,564
176,233
184,072
185,841
187,636
272,885
297,028
303,864
310,099
321,990
319,898
322,204
325,963
337,176
332,649
335,524
379,888
389,229
382,812
384,216
385,730
396,754
389,903
405,721
406,258
435,715
432,129
432,745
433,436
453,002
460,092
475,831
476,643
509,660
510,662
511,213
516,060
516,457
516,888
531,302
533,387
533,387531,302516,888516,457516,060511,213510,662509,660476,643475,831460,092453,002433,436432,745432,129435,715406,258405,721389,903396,754385,730384,216382,812389,229379,888335,524332,649337,176325,963322,204319,898321,990310,099303,864297,028272,885187,636185,841184,072176,233171,564124,281123,479124,918-40,29652,27201,58400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-29,741
Operating Income-29,741-29,741
 
Operating Expense (+$)
Research Development20,102
Selling General Administrative9,639
Selling And Marketing Expenses-
Operating Expense29,74129,741
 
Net Interest Income (+$)
Interest Income1,657
Interest Expense-686
Other Finance Cost-0
Net Interest Income971
 
Pretax Income (+$)
Operating Income-29,741
Net Interest Income971
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-28,770-29,741
EBIT - interestExpense = -686
-28,771
-28,085
Interest Expense686
Earnings Before Interest and Taxes (EBIT)--28,084
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-28,770
Tax Provision-1
Net Income From Continuing Ops-28,771-28,771
Net Income-28,771
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--971
 

Technical Analysis of Regulus Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Regulus Therapeutics Inc. The general trend of Regulus Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Regulus Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Regulus Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3 < 3.25 < 3.4.

The bearish price targets are: 2.14 > 1.8499 > 1.76.

Tweet this
Regulus Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Regulus Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Regulus Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Regulus Therapeutics Inc. The current macd is 0.36305265.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Regulus Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Regulus Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Regulus Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Regulus Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartRegulus Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Regulus Therapeutics Inc. The current adx is 46.89.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Regulus Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Regulus Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Regulus Therapeutics Inc. The current sar is 1.81219356.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Regulus Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Regulus Therapeutics Inc. The current rsi is 75.92. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
Regulus Therapeutics Inc Daily Relative Strength Index (RSI) ChartRegulus Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Regulus Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Regulus Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Regulus Therapeutics Inc Daily Stochastic Oscillator ChartRegulus Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Regulus Therapeutics Inc. The current cci is 89.27.

Regulus Therapeutics Inc Daily Commodity Channel Index (CCI) ChartRegulus Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Regulus Therapeutics Inc. The current cmo is 55.31.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Regulus Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartRegulus Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Regulus Therapeutics Inc. The current willr is -36.84210526.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Regulus Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Regulus Therapeutics Inc Daily Williams %R ChartRegulus Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Regulus Therapeutics Inc.

Regulus Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Regulus Therapeutics Inc. The current atr is 0.30971929.

Regulus Therapeutics Inc Daily Average True Range (ATR) ChartRegulus Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Regulus Therapeutics Inc. The current obv is 235,073,893.

Regulus Therapeutics Inc Daily On-Balance Volume (OBV) ChartRegulus Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Regulus Therapeutics Inc. The current mfi is 94.89.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Regulus Therapeutics Inc Daily Money Flow Index (MFI) ChartRegulus Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Regulus Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Regulus Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Regulus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.919
Ma 20Greater thanMa 502.182
Ma 50Greater thanMa 1001.707
Ma 100Greater thanMa 2001.520
OpenGreater thanClose2.810
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Regulus Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Regulus Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Regulus Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Regulus Therapeutics Inc

I send you an email if I find something interesting about Regulus Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Regulus Therapeutics Inc.

Receive notifications about Regulus Therapeutics Inc in your mailbox!